Novel Approaches Across Non-Hodgkin Lymphoma Subtypes Demonstrate Continued Benefit
Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.
Related Articles
Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis
Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.
FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab
The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.
Assessing HER2 Status Across Tumor Types
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Plinabulin Plus Docetaxel Boosts OS in Pretreated EGFR Wild-Type NSCLC
The DUBLIN-3 trial showed plinabulin plus docetaxel improved survival in EGFR wild-type non–small cell lung cancer.
Ibrilatazar Plus Chemotherapy Elicits Promising Activity in Recurrent Endometrial Cancer
Ibrilatazar plus paclitaxel/carboplatin led to a 100% disease-control rate in patients with advanced/recurrent endometrial cancer and was well tolerated.
More Precise Classifications of Non–Clear Cell RCC Are Required to Improve Personalized Treatment
Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.
TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL
Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.
FDA Grants Orphan Drug Designation to Tebapivat for MDS
The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.
CLL Disease State and Goals of Treatment
The Holistic Value of Targeted Time-Limited Therapy in Chronic Lymphocytic
Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation
Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume…